Bruker to acquire EliTechGroup
March 1, 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Binx enters into distribution agreement with Cardinal Health
Feb. 21 2024—Binx Health announced a national distribution agreement with Cardinal Health to expand access to care with its CLIA-waived, FDA-cleared Binx IO.
Roche, PathAI to develop AI digital pathology algorithms
Feb. 14, 2024—Roche announced it has entered into an agreement with PathAI to develop AI-enabled digital pathology algorithms for Roche Tissue Diagnostics’ companion diagnostics business.
Bio-Rad publishes third workbook in QC series
Feb. 13, 2024—Bio-Rad Laboratories has published its third workbook in a series that offers Professional Acknowledgement for Continuing Education credits.
Proscia gets FDA 510(k) clearance for Concentriq AP-Dx
Feb. 12, 2024—Proscia has received FDA 510(k) clearance for its Concentriq AP-Dx diagnostic software for primary diagnosis.
Health Canada approves Corista DP3 platform
Feb. 7, 2024—Corista announced it has received a class II medical device license from Health Canada for its DP3 platform, a web-based image-management system for digital pathology.
CellaVision, Sysmex sign strategic alliance agreement
Feb. 6, 2024—CellaVision and Sysmex announced a strategic alliance agreement that expands their mutual commitment until 2038.
Beckman Coulter unveils DxC 500 AU chemistry analyzer
Feb. 5, 2024—Beckman Coulter Diagnostics unveiled its DxC 500 AU chemistry analyzer today at Medlab Middle East in Dubai.
FDA clears Hologic Genius digital cytology system
Feb. 2, 2024—Hologic announced that its Genius Digital Diagnostics system with the Genius Cervical AI algorithm has received clearance from the FDA, making it the first FDA-cleared digital cytology system that combines deep-learning–based artificial intelligence with advanced volumetric imaging technology to help identify precancerous lesions and cervical cancer cells.
iSpecimen, TriMetis partner to enhance tissue-based research
Jan. 24, 2024—The company iSpecimen, an online marketplace that connects life science researchers seeking human biospecimens for medical research with health care organizations that have such specimens, announced it has entered into a pilot program agreement with TriMetis Life Sciences.